Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Assets: 2016-2024

Historic Non-Current Assets for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $106.8 million.

  • Akebia Therapeutics' Non-Current Assets fell 1.13% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year decrease of 1.13%. This contributed to the annual value of $106.8 million for FY2024, which is 13.53% down from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Non-Current Assets is $106.8 million, which was down 13.53% from $123.6 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Non-Current Assets ranged from a high of $272.7 million in FY2020 and a low of $106.8 million during FY2024.
  • In the last 3 years, Akebia Therapeutics' Non-Current Assets had a median value of $123.6 million in 2023 and averaged $133.8 million.
  • Data for Akebia Therapeutics' Non-Current Assets shows a maximum YoY crashed of 40.93% (in 2020) over the last 5 years.
  • Akebia Therapeutics' Non-Current Assets (Yearly) stood at $272.7 million in 2020, then decreased by 5.32% to $258.2 million in 2021, then slumped by 33.82% to $170.9 million in 2022, then dropped by 27.69% to $123.6 million in 2023, then dropped by 13.53% to $106.8 million in 2024.